Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
Authors
Keywords
-
Journal
BMC CANCER
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-14
DOI
10.1186/s12885-020-07142-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
- (2019) Ken Masuda et al. BMC CANCER
- Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti‐Programmed Cell Death 1 Monotherapy for Advanced Non‐Small Cell Lung Cancer
- (2019) Mari Aso et al. ONCOLOGIST
- Management of immune checkpoint inhibitor‐related rheumatic adverse events
- (2019) Jiaxin Zhou et al. Thoracic Cancer
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
- (2019) Puyuan Xing et al. Journal for ImmunoTherapy of Cancer
- Toxicities Associated With PD-1/PD-L1 Blockade
- (2018) Daniel Y. Wang et al. CANCER JOURNAL
- Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead
- (2018) Pradnya D. Patil et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Immune‐Related Adverse Events with Clinical Benefit in Patients with Advanced Non‐Small‐Cell Lung Cancer Treated with Nivolumab
- (2018) Yukihiro Toi et al. ONCOLOGIST
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study
- (2018) Naoto Okada et al. CLINICAL THERAPEUTICS
- Immune-related adverse events of immune checkpoint inhibitors: a brief review
- (2018) G. Myers Current Oncology
- Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
- (2018) Yukihiro Toi et al. JAMA Oncology
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now